Care Bare Rx vs Get Thin MD
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Care Bare Rx
Best for LGBTQ+-inclusive compounded GLP-1 telehealthStarting at $199/mo
Get Thin MD
Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also availableStarting at $169/mo
Side-by-Side Comparison
| Feature | Care Bare Rx | Get Thin MD |
|---|---|---|
| Overall Score | 7.4/10 | ✓7.9/10 |
| Starting Price | $199/mo | ✓$169/mo |
| Editorial Rating | 3.7 ★ /5 | ✓4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Care Bare Rx
Pros
- ✓Explicit LGBTQ+-inclusive, 'self-care with pride' positioning — one of the few GLP-1 telehealth brands with this framing
- ✓All 50 states + Puerto Rico coverage
- ✓Offers both compounded options ($199/mo) and brand-name Ozempic ($705/mo) — unusual flexibility in the compounded-first telehealth segment
- ✓Same named medical team as Breeze Meds and Synergy Rx: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
- ✓Four named 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx)
- ✓No FDA warnings or litigation on record
Cons
- ✗Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Breeze Meds and Synergy Rx — the three brands are white-labeled storefronts on top of one underlying operation, not three independent providers
- ✗Compounded medications are not FDA-approved
- ✗Despite the LGBTQ+ positioning, no formal gender-affirming care pathway or HRT integration is mentioned — the inclusive framing is editorial rather than a clinical specialty
- ✗Limited accreditation transparency beyond LegitScript claim — no PCAB/ACHC seal on site
- ✗Pharmacy partners are named but per-batch third-party testing and accreditation details are not independently disclosed
Get Thin MD
Pros
- ✓3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
- ✓Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
- ✓Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
- ✓Nationwide availability with async evaluation — no in-person visit required
- ✓Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
- ✓Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."
Cons
- ✗Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
- ✗Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
- ✗State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
- ✗Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
- ✗Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix
Our Verdict
Get Thin MD edges out Care Bare Rx with a higher overall score of 7.9/10 and is particularly strong for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available. Care Bare Rx remains a solid alternative, especially if you're looking for LGBTQ+-inclusive compounded GLP-1 telehealth.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.